Comparative Pharmacology
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus MUCOMYST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSTEINE HYDROCHLORIDE versus MUCOMYST.
CYSTEINE HYDROCHLORIDE vs MUCOMYST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cysteine hydrochloride serves as a precursor to glutathione, an important antioxidant. It also provides a source of cysteine for protein synthesis and acts as a mucolytic agent by reducing disulfide bonds in mucus glycoproteins, thereby decreasing viscosity.
Acetylcysteine reduces mucus viscosity by breaking disulfide bonds in mucoproteins, thereby facilitating mucus clearance. It also serves as a precursor to glutathione, providing antioxidant effects and hepatoprotection in acetaminophen overdose.
Intravenous: 0.8-1 g/m²/day divided every 6 hours for acetaminophen poisoning; for parenteral nutrition, 0.66-1.7 g of cysteine/kg/day (as hydrochloride).
Acetaminophen overdose: 140 mg/kg orally as loading dose, then 70 mg/kg every 4 hours for 17 doses (total 1330 mg/kg). For inhalation: 3-5 mL of 20% solution via nebulization 3-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 1.5-3 hours in adults with normal renal function; prolonged in renal impairment (up to 8-10 hours in severe cases).
Terminal elimination half-life is approximately 5.6 hours (range 5–6.5 h) in adults; prolonged in patients with hepatic impairment. For acetaminophen overdose, a second prolonged phase (>15 h) may occur.
Renal: 40-60% as unchanged drug and metabolites; fecal: <5%; minor biliary elimination; route of administration (e.g., intravenous) influences exact percentages.
Primarily renal as inactive metabolites (e.g., N-acetylcysteine, cysteine, inorganic sulfate). Less than 30% excreted unchanged in urine. Minor fecal elimination.
Category C
Category C
Mucolytic
Mucolytic